Monday Apr 14
Reevaluating Gilead Sciences After The Sell-Off
Background : On April 7, Seeking Alpha published an article I wrote on Gilead Sciences .
HIV & AIDS Information :: Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment
Investigators in the United States have developed a risk score to predict which people living with HIV have the highest risk of developing chronic kidney disease.
BMSa s Attachment Inhibitor Shows Promise
A promising trial of Bristol-Myers Squibb's investigational attachment inhibitor GS-663068 raises hope of the introduction of a new antiretroviral drug class, which would especially benefit those with multidrug resistance, aidsmap reports.